Background: The COVID-19 pandemic continues to be a major worldwide health problem. The present study aims to contribute to surveillance of the immune and clinical response of vaccines to SARS-CoV-2. Methods: Observational medication study on acquired immunity and effectiveness of vaccines. Population: 620 workers in the health service of Almansa (Spain). Representative sample of 150 individuals. Sociodemographic, clinical, and epidemiological data and samples were recorded to determine anti-SARS-CoV-2 serum IgG levels 6 and 9 months after vaccination with Pfizer. Results: Mean age 46.45 years; 76% women; 85.1% working in a hospital. 19.3% had had COVID-19 in the year prior to vaccination. 96.7% were fully vaccinated with Pfizer/BioNTech. At 6 months, 100% seropositivity and mean IgG levels of 3017.2 AU/ml. Significant variations in IgG levels in individuals with prior COVID-19 infection and smokers. At 9 months, 99.3% remained seropositive; 2.8% infected after vaccination. The repeated measures analysis showed a difference in means of 669.0 AU/ml (significant decrease in IgG levels of 28.9%). Conclusion: Antibody levels remained positive 6 and 9 months after vaccination, although IgG levels were found to decay.
References
[1]
Ministerio de Sanidad. Instituto de Salud Carlos III (2022) Estrategia de Vigilancia Y Control Frente a COVID-19 Tras la Fase Aguda de la Pandemia.
https://www.sanidad.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov/documentos/Nueva_estrategia_vigilancia_y_control.pdf
[2]
de Sanidad, M. (2022) Situación En Espana.
https://www.sanidad.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov/documentos/Actualizacion_630_COVID-19.pdf
[3]
World Health Organization (2022) WHO Coronavirus (COVID-19) Dashboard. https://covid19.who.int/
[4]
Ministerio de Sanidad (2022) Situación Actual Coronavirus.
https://www.sanidad.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov/situacionActual.htm
[5]
Centro de coordinación de alertas y emergencias sanitarias (2022) Actualización de la situación epidemiológica de las variantes de SARS-CoV-2 en Espana.
https://www.sanidad.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov/documentos/20220113_MICROBIOLOGIA.pdf
[6]
Grupo Consultivo Técnico sobre la Evolución del Virus SARS-CoV-2 (2022) Clasificación de la variante ómicron (B.1.1.529) del SARS-CoV-2como variante preocupante.
https://www.who.int/es/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern
[7]
Centers for Disease Control and Prevention (2022) Variante ómicron: Lo que debe.
https://espanol.cdc.gov/coronavirus/2019-ncov/variants/omicron-variant.html
[8]
Khoury, D.S., Cromer, D., Reynaldi, A., Schlub, T.E., Wheatley, A.K., Juno, J.A., et al. (2021) Neutralizing Antibody Levels Are Highly Predictive of Immune Protection from Symptomatic SARS-CoV-2 Infection. Nature Medicine, 27, 1205-1211.
https://doi.org/10.1038/s41591-021-01377-8
[9]
Beh, C.C., Zulkufli, N.S., Loh, L.M., Cheng, K.W., Choo, L.M., Cheah, M.W., et al. (2021) SARS-CoV-2 Seroprevalence and Antibody Trends in Vaccinated, Multi-Ethnic Healthcare Employees. Tropical Biomedicine, 38, 552-560.
https://doi.org/10.47665/tb.38.4.098
[10]
Brisotto, G., Muraro, E., Montico, M., Corso, C., Evangelista, C., Casarotto, M., et al. (2021) IgG Antibodies against SARS-CoV-2 Decay But Persist 4 Months after Vaccination in a Cohort of Healthcare Workers. Clinica Chimica Acta, 523, 476-482. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8555109/
https://doi.org/10.1016/j.cca.2021.10.035
[11]
World Health Organization (2021) Estimating COVID-19 Vaccine Effectiveness against Severe Acute Respiratory Infections (SARI) Hospitalisations Associated with Laboratory-Confirmed SARS-CoV-2: An Evaluation Using the Test-Negative Design: Guidance Document. https://apps.who.int/iris/handle/10665/341111
[12]
Krause, P.R., Fleming, T.R., Peto, R., Longini, I.M., Figueroa, J.P., Sterne, J.A.C., et al. (2021) Considerations in Boosting COVID-19 Vaccine Immune Responses. The Lancet, 398, 1377-1380. https://doi.org/10.1016/S0140-6736(21)02046-8
[13]
Grupo Consultivo Técnico de la OMS sobre la Composición de las Vacunas contra la COVID-19 (TAG-CO-VAC) (2022) Declaración provisional sobre las vacunas contra la COVID-19, en el contexto de la circulación de la variante ómicron del SARS-CoV-2, del Grupo Consultivo Técnico de la OMS sobre la Composición de las Vacunas contra la COVID-19 (TAG-CO-VAC).
https://www.who.int/groups/technical-advisory-group-on-covid-19-vaccine-composition-(tag-co-vac)
[14]
Zurac, S.B., Nichita, L., Mateescu, B., Mogodici, C., Bastian, A., Popp, C., et al. (2021) COVID-19 Vaccination and IgG and IgA Antibody Dynamics in Healthcare Workers. Molecular Medicine Reports, 24, Article No. 578.
https://doi.org/10.3892/mmr.2021.12217
[15]
Chivu-Economescu, M., Bleotu, C., Grancea, C., Chiriac, D., Botezatu, A., Iancu, I.V., et al. (2022) Kinetics and Persistence of Cellular and Humoral Immune Responses to SARS-CoV-2 Vaccine in Healthcare Workers with or without Prior COVID-19. Journal of Cellular and Molecular Medicine, 26, 1293-1305.
https://doi.org/10.1111/jcmm.17186
[16]
Ikezaki, H., Nomura, H. and Shimono, N. (2022) Dynamics of Anti-Spike IgG Antibody Level after the Second BNT162b2 COVID-19 Vaccination in Health Care Workers. Journal of Infection and Chemotherapy Home, 28, 802-805.
https://doi.org/10.1016/j.jiac.2022.02.024
[17]
Ministerio de Sanidad (2022) Actualización no 562. Enfermedad por el coronavirus (COVID-19).
https://www.sanidad.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov/documentos/Actualizacion_562_COVID-19.pdf
[18]
Ministerio de Sanidad (2022) Estrategia de vacunación COVID-19 en Espana.
https://www.sanidad.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov/vacunaCovid19.htm
[19]
Cham, J., Pandey, A.C., New, J., Huynh, T., Hong, L., Orendain, N., et al. (2022) 6 Month Serologic Response to the Pfizer-BioNTech COVID-19 Vaccine among Healthcare Workers. PLOS ONE, 17, e0266781.
[20]
Rodgers, M.A., Olivo, A., Harris, B.J., Lark, C., Luo, X., Berg, M.G., et al. (2022) Detection of SARS-CoV-2 Variants by Abbott Molecular, Antigen, and Serological Tests. Journal of Clinical Virology, 147, Artice ID: 105080.
https://doi.org/10.1016/j.jcv.2022.105080
[21]
Narasimhan, M., Mahimainathan, .L, Araj, E., Clark, A.E., Markantonis, J., Green, A., et al. (2021) Clinical Evaluation of the Abbott Alinity SARS-CoV-2 Spike-Specific Quantitative IgG and IgM Assays among Infected, Recovered, and Vaccinated Groups. Journal of Clinical Microbiology, 59, e00388-21.
https://doi.org/10.1128/JCM.00388-21
[22]
Ministerio de sanidad (2021) Estrategia De Detección Precoz, Vigilancia Y Control De COVID-19 Actualizado a 26 de febrero de 2021 Este documento ha sido aprobado por la Ponencia de Alertas y Planes de Preparación y Respuesta y por la Comisión de Salud Pública del Consejo Interterrito.
https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov/documentos/COVID19_Estrategia_vigilancia_y_control_e_indicadores.pdf
[23]
Zhong, D., Xiao, S., Debes, A.K., Egbert, E.R., Caturegli, P., Colantuoni, E., et al. (2021) Durability of Antibody Levels after Vaccination with mRNA SARS-CoV-2 Vaccine in Individuals with or without Prior Infection. Journal of the American Medical Association, 326, 2524-2526. https://pubmed.ncbi.nlm.nih.gov/34724529/
https://doi.org/10.1001/jama.2021.19996
[24]
Buonfrate, D., Piubelli, C., Gobbi, F., Martini, D., Bertoli, G., Ursini, T., et al. (2021) Antibody Response Induced by the BNT162b2 mRNA COVID-19 Vaccine in a Cohort of Health-Care Workers, with or without Prior SARS-CoV-2 Infection: A Prospective Study. Clinical Microbiology and Infection, 27, 1845-1850.
https://doi.org/10.1016/j.cmi.2021.07.024
[25]
Terpos, E., Trougakos, I.P., Karalis, V., Ntanasis-Stathopoulos, I., Gumeni, S., Apostolakou, F., et al. (2021) Kinetics of Anti-SARS-CoV-2 Antibody Responses 3 Months Post Complete Vaccination with BNT162B2; A Prospective Study in 283 Health Workers. Cells 2021, 10, Article 1942. https://doi.org/10.3390/cells10081942
[26]
Bayram, A., Demirbakan, H., Günel Karadeniz, P., Erdogan, M. and Kocer, I. (2021) Quantitation of Antibodies against SARS-CoV-2 Spike Protein after Two Doses of CoronaVac in Healthcare Workers. Journal of Medical Virology, 93, 5560-5567.
https://doi.org/10.1002/jmv.27098
[27]
Hillus, D., Schwarz, T., Tober-Lau, P., Vanshylla, K., Hastor, H., Thibeault, C., et al. (2021) Safety, Reactogenicity, and Immunogenicity of Homologous and Heterologous Prime-Boost Immunisation with ChAdOx1 nCoV-19 and BNT162b2: A Prospective Cohort Study. The Lancet Respiratory Medicine, 9, 1255-1265.
https://doi.org/10.1016/S2213-2600(21)00357-X
[28]
Yigit, M., Ozkaya-Parlakay, A., Cosgun, Y., Ince, Y.E., Bulut, Y.E. and Senel, E. (2022) Should a Third Booster Dose Be Scheduled after Two Doses of CoronaVac? A Single-Center Experience. Journal of Medical Virology, 94, 287-290.
https://doi.org/10.1002/jmv.27318
[29]
Havervall, S., Marking, U., Greilert-Norin, N., Ng, H., Gordon, M., Salomonsson, A.C., et al. (2021) Antibody Responses after a Single Dose of ChAdOx1 nCoV-19 Vaccine in Healthcare Workers Previously Infected with SARS-CoV-2. EBioMedicine, 70, Article 103523. https://doi.org/10.1016/j.ebiom.2021.103523
[30]
Hansen, C.B., Jarlhelt, I., Hasselbalch, R.B., Hamm, S.R., Fogh, K., Pries-Heje, M.M., et al. (2021) Antibody-Dependent Neutralizing Capacity of the SARS-CoV-2 Vaccine BNT162b2 with and without Previous COVID-19 Priming. Journal of Internal Medicine, 290, 1272-1274. https://doi.org/10.1111/joim.13366
[31]
Ebinger, J.E., Fert-Bober, J., Printsev, I., Wu, M., Sun, N., Prostko, J.C., et al. (2021) Antibody Responses to the BNT162b2 mRNA Vaccine in Individuals Previously Infected with SARS-CoV-2. Nature Medicine, 27, 981-984.
https://doi.org/10.1038/s41591-021-01325-6
[32]
Terpos, E., Trougakos, I.P., Apostolakou, F., Charitaki, I., Sklirou, A.D., Mavrianou, N., et al. (2021) Age-Dependent and Gender-Dependent Antibody Responses against SARS-CoV-2 in Health Workers and Octogenarians after Vaccination with the BNT162b2 mRNA Vaccine. American Journal of Hematology, 96, E257-E259.
https://doi.org/10.1002/ajh.26185
[33]
El-Ghitany, E.M., Hashish, M.H., Farag, S., Omran, E.A., Farghaly, A.G. and El-Moez Azzam, N.F.A. (2022) Determinants of the Development of SARS-CoV-2 Anti-Spike Immune-Response after Vaccination among Healthcare Workers in Egypt. Vaccines, 10, Article 174. https://doi.org/10.3390/vaccines10020174
[34]
Terpos, E., Karalis, V., Ntanasis-Stathopoulos, I., Evangelakou, Z., Gavriatopoulou, M., Manola, M.S., et al. (2022) Comparison of Neutralizing Antibody Responses at 6 Months Post Vaccination with BNT162b2 and AZD1222. Biomedicines, 10, Article 338. https://www.mdpi.com/2227-9059/10/2/338/htm
https://doi.org/10.3390/biomedicines10020338
[35]
Rode, O.D., Bodulic, K., Zember, S., Balent, N.C., da Novokmet, A., Culo, M., et al. (2022) Decline of Anti-SARS-CoV-2 IgG Antibody Levels 6 Months after Complete BNT162b2 Vaccination in Healthcare Workers to Levels Observed following the First Vaccine Dose. Vaccines, 10, Article 153.
https://doi.org/10.3390/vaccines10020153
[36]
Papadopoulos, D., Ntanasis-Stathopoulos, I., Gavriatopoulou, M., Evangelakou, Z., Malandrakis, P., Manola, M.S., et al. (2022) Predictive Factors for Neutralizing Antibody Levels Nine Months after Full Vaccination with BNT162b2: Results of a Machine Learning Analysis. Biomedicines, 10, Article 204.
https://doi.org/10.3390/biomedicines10020204
[37]
Goel, R.R., Painter, M.M., Apostolidis, S.A., Mathew, D., Meng, W., Rosenfeld, A.M., et al. (2021) mRNA Vaccines Induce Durable Immune Memory to SARS-CoV-2 and Variants of Concern. Science, 374, 6572. https://doi.org/10.1126/science.abm0829
[38]
Goel, R.R., Painter, M.M., Apostolidis, S.A., Mathew, D., Meng, W., Rosenfeld, A.M., et al. (2021) mRNA Vaccination Induces Durable Immune Memory to SARS-CoV-2 with Continued Evolution to Variants of Concern. bioRxiv: The Preprint Server for Biology.
https://www.biorxiv.org/content/10.1101/2021.08.23.457229v1
[39]
Notarte, K.I., Guerrero-Arguero, I., Velasco, J.V., Ver, A.T., Oliveira, M.H.S., Catahay, J.A., et al. (2022) Characterization of the Significant Decline in Humoral Immune Response Six Months Post-SARS-CoV-2 mRNA Vaccination: A Systematic Review. Journal of Medical Virology, 94, 2939-2961.
https://onlinelibrary.wiley.com/doi/10.1002/jmv.27688 https://doi.org/10.1101/2021.12.10.21267593
[40]
Benning, L., Morath, C., Bartenschlager, M., Reineke, M., Tollner, M., Nusshag, C., et al. (2022) Neutralizing Antibody Activity against the B.1.617.2 (Delta) Variant 8 Months after Two-Dose Vaccination with BNT162b2 in Health Care Workers. Clinical Microbiology and Infection, 28, 1024.E7-1024.E12.
https://doi.org/10.1016/j.cmi.2022.01.011
[41]
Haveri, A., Solastie, A., Ekstrom, N., Osterlund, P., Nohynek, H., Nieminen, T., et al. (2022) Neutralizing Antibodies to SARS-CoV-2 Omicron Variant after Third mRNA Vaccination in Health Care Workers and Elderly Subjects. European Journal of Immunology, 52, 816-824. https://doi.org/10.1002/eji.202149785
[42]
Collier, D.A., Ferreira, I.A.T.M., Kotagiri, P., Datir, R.P., Lim, E.Y., Touizer, E., et al. (2021) Age-Related Immune Response Heterogeneity to SARS-CoV-2 Vaccine BNT162b2. Nature, 596, 417-422. https://doi.org/10.1101/2021.02.03.21251054
[43]
Tsatsakis, A., Vakonaki, E., Tzatzarakis, M., Flamourakis, M., Nikolouzakis, T.K., Poulas K, et al. (2021) Immune Response (IgG) following Full Inoculation with BNT162b2 COVID-19 mRNA among Healthcare Professionals. International Journal of Molecular Medicine, 48, Article No. 200.
https://doi.org/10.3892/ijmm.2021.5033
[44]
Plebani, M., Cosma, C. and Padoan, A. (2021) SARS-CoV-2 Antibody Assay after Vaccination: One Size Does Not Fit All. Clinical Chemistry and Laboratory Medicine, 59, e380-e381.
https://www.degruyter.com/document/doi/10.1515/cclm-2021-0703/html
https://doi.org/10.1515/cclm-2021-0703
[45]
Moncunill, G., Aguilar, R., Ribes, M., Ortega, N., Rubio, R., Salmerón, G., et al. (2022) Determinants of Early Antibody Responses to COVID-19 mRNA Vaccines in a Cohort of Exposed and Naive Healthcare Workers. EBioMedicine, 75, Article 103805. https://doi.org/10.1016/j.ebiom.2021.103805
